SIREN : 830942231
BIOTERIVE is a French company founded 8 years ago, specialized in the sector Supérettes. Based in AUTERIVE (31190), this company of category PME shows in 2024 a revenue of 1.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1 188 629 € | 1 119 982 € | 1 179 021 € | N/C | N/C |
| Net income | 22 088 € | 10 494 € | 6 487 € | 2 776 € | 13 780 € |
| EBITDA | 44 743 € | 37 715 € | 40 192 € | N/C | N/C |
| Net margin | 1.9% | 0.9% | 0.6% | N/C | N/C |
In 2024, BIOTERIVE achieves revenue of 1.2 M€. Revenue is growing positively over 5 years (CAGR: +0.4%). Vs 2023: +6%. After deducting consumption (828 k€), gross margin stands at 360 k€, i.e. a rate of 30%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 45 k€, representing 3.8% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 22 k€, i.e. 1.9% of revenue. This profit can be retained or distributed to shareholders.
1 188 629 €
360 458 €
44 743 €
24 089 €
22 088 €
3.8%
The debt ratio (= Financial debt / Equity x 100) stands at 271%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 18%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.8 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 3.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
270.958%
18.429%
3.604%
4.782
In 2024, the debt ratio of BIOTERIVE (270.96) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of BIOTERIVE (18.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of BIOTERIVE (4.78) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 0.00. Alert: short-term debt exceeds current assets. Risk of payment difficulties without cash reinforcement. The interest coverage ratio (= EBIT / Interest expenses) is 12.1x. Operating income very largely covers interest expenses: high safety margin.
0.0
12.096
In 2024, the liquidity ratio of BIOTERIVE (0.00) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of BIOTERIVE (12.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 34 days. Excellent situation: suppliers finance 34 days of the operating cycle (retail model). WCR is negative (-11 days): operations structurally generate cash.
-36 705 €
0 j
34 j
0 j
-11 j
Based on 551 transactions of similar company sales in 2024, the value of BIOTERIVE is estimated at 213 492 € (range 93 048€ - 433 981€). With an EBITDA of 44 743€, the sector multiple of 4.7x is applied. The price/revenue ratio is 0.23x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 551 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOTERIVE with other companies in the same sector:
The revenue of BIOTERIVE in 2024 is 1.2 M€.
Yes, BIOTERIVE generated a net profit of 22 k€ in 2024.
The headquarters of BIOTERIVE is located in AUTERIVE (31190), in the department Haute-Garonne.
The tax return of BIOTERIVE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOTERIVE operates in the sector Supérettes (NAF code 47.11C). See the 'Sector positioning' section above to compare the company with its competitors.